Phase 2a Placebo-Controlled Study of VTX3232 Alone or in Combination With Semaglutide in Obesity

What Was Tested

In this phase 2 trial, researchers set out to test Semaglutide.

This study evaluated the safety of VTX3232 administered alone or in combination with semaglutide in participants with obesity.

The study consisted of a 30-day screening period, a 12-week double-blind treatment period, and a 30-day follow-up period.

It had four arms (groups): Placebo (placebo comparator), one (experimental), Placebo + Semaglutide (active comparator) and one (experimental).

The registry classes the interventions as drug.

Who Took Part

The registry lists 175 actual participants took part.

It was open to people of any sex aged from 18 years up to 80 years.

Healthy volunteers were not accepted; participants needed the condition being studied.

Examples of who could join: Participants are male or female ≥ 18 years up to ≤ 80 years of age. Ability to comply with study requirements. BMI ≥ 30.0 to ≤ 42.0 kg/m2 at screening. History of at least one self-reported unsuccessful dietary effort to lose body weight.

The full record lists 7 inclusion and 11 exclusion criteria; among the exclusions: obesity induced by endocrinologic disorders, or diagnosed genetic or syndromic forms of obesity; have any prior diagnosis of diabetes mellitus; clinically relevant medical condition(s) that put the participant at risk or will make implementation of the protocol or interpretation of the study difficult.

How the Study Was Run

It was run as a randomized, parallel-group and quadruple-blind study.

Because people in this Semaglutide study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

The Semaglutide group and the comparison group ran side by side rather than switching.

Neither the participants nor the staff measuring them knew who was on Semaglutide, so expectations could not easily colour the readings.

Those kept unaware of assignments: participant, care provider, investigator and outcomes assessor.

It started in 2025-01-07 with completion listed for 2025-09-10.

It ran at 14 sites in United States (14).

Its stated primary purpose is treatment.

What Was Measured

Researchers chose this as the main measure: Number of Participants With Any Treatment Emergent Adverse Events (TEAEs).

It also tracked 1 secondary outcome, for example Percent Change From Baseline to Week 12 in High-Sensitivity C-Reactive Protein (Hs-CRP) Level.

What This Means in Plain Language

Put simply, this is a phase 2, randomized trial of Semaglutide in 175 people.

The trial is marked completed; results are posted on the registry, and this page does not restate them.

More context: the Semaglutide compound page, all human trials.